Caricamento...
Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma
Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (PDAC) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with PDAC. In this study, we evaluate the anti‐PDAC effects of LY‐1816, a n...
Salvato in:
| Pubblicato in: | Cancer Sci |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6447837/ https://ncbi.nlm.nih.gov/pubmed/30618127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13929 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|